Effect of bosentan on systemic and renal inflammatory markers in patients with diabetic nephropathy on angiotensin II receptor blockers.
Phase of Trial: Phase III
Latest Information Update: 14 Jun 2010
At a glance
- Drugs Bosentan (Primary)
- Indications Diabetic nephropathies
- Focus Biomarker; Therapeutic Use
- 14 Jun 2010 Actual patient number (1) added as reported by ClinicalTrials.gov.
- 14 Jun 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Jun 2009 Actual initiation date changed from 1 Jun 2008 to 1 Jan 2009 as reported by ClinicalTrials.gov.